Anxiolytics, hypnotics, and antidepressants dispensed to adolescents in a French region in 2002

@article{Mancini2006AnxiolyticsHA,
  title={Anxiolytics, hypnotics, and antidepressants dispensed to adolescents in a French region in 2002},
  author={Julien Mancini and Xavier Thirion and Alain Masut and Carine Saillard and Vincent Pradel and Fanny Romain and M J Jean Pastor and Christine Coudert and Jo{\"e}lle Micallef},
  journal={Pharmacoepidemiology and Drug Safety},
  year={2006},
  volume={15}
}
This study proposes to complete declarative studies by describing the prescriptions of anxiolytics, hypnotics, and antidepressants dispensed to adolescents in a French region in 2002. 
Antidepressant use and off‐label prescribing in children and adolescents in Dutch general practice (2001–2005)
To study the use of antidepressants in children and adolescents in Dutch general practice in 2001 and 2005 and to determine off‐label prescribing.
Hypnotic hazards: adverse effects of zolpidem and other z-drugs
Zolpidem, zopiclone and zaleplon are hypnotics with similar pharmacology to benzodiazepines. In
Psychotropic medication use in children and adolescents: a study from France.
TLDR
The extent and patterns of psychotropic medication use in children and adolescents enrolled in a large health plan (MGEN) in France, and its evolution in recent years, are described.
Polypharmacy with antidepressants in children and adolescents.
TLDR
Preliminary evidence points to the potential clinical usefulness of some polypharmacy patterns, although there is still little efficacy and safety information, and further research on patients with co-morbidities or more severe conditions is needed.
Dispensing of anxiolytics and hypnotics in southeastern France: demographic factors and determinants of geographic variations
TLDR
The prevalence of mental illness and that of chronic illness were independently and positively associated with overall and chronic use; unemployment rates and mean family income were positively associated only with overall use.
Le traitement pharmacologique de l’insomnie en pédopsychiatrie
TLDR
Pharmacological treatment of insomnia should be considered in patients with attention deficit hyperactivity disorder in which sleep disturbances can be aggravated by psycho stimulant treatment, in autism spectrum disorders, and in the anxiety/depression.
Pharmacoepidemiological research using French reimbursement databases: yes we can!
TLDR
To describe the reimbursement databases available in France for pharmacoepidemiological research and their use, the use of these databases is described.
Psychotropic medication in the French child and adolescent population: prevalence estimation from health insurance data and national self-report survey data
TLDR
A disparity between the prevalence of dispensed prescriptions and the self-report of actual use of psychotropics has been highlighted by the ESCAPAD study which shows that these treatments are widely used as "self-medication".
Recent international trends in psychotropic medication prescriptions for children and adolescents
  • H. Steinhausen
  • Psychology, Medicine
    European Child & Adolescent Psychiatry
  • 2014
TLDR
Considering the increasing numbers of children and adolescents seen in psychiatric services, the increase of psychotropic medications is less strong though still pronounced enough to stimulate further reflections on the use of these interventions.
Antidepressant usage by South African children and adolescents: A drug utilisation review
TLDR
There were significant differences with regard to the different age groups, gender, type of prescriber and appropriateness vs. inappropriate antidepressant prescribing in children and adolescents in South Africa.
...
...

References

SHOWING 1-10 OF 35 REFERENCES
Use of psychotropic drugs in an urban adolescent population: the impact of health‐related variables, lifestyle and sociodemographic factors—The Oslo Health Study 2000–2001
The aims of the study were to examine use of psychotropic drugs among 15–16 years old adolescents and to study the association between use of drugs and health‐related, lifestyle and sociodemographic
Paroxetine must not be given to patients under 18
  • F. Waechter
  • Medicine, Psychology
    BMJ : British Medical Journal
  • 2003
The Medicines and Healthcare Products Regulatory Agency (MHRA) has advised that the antidepressant paroxetine (marketed as Seroxat) should not be prescribed for children or adolescents. It did so on
Buprenorphine prescription by general practitioners in a French region.
Multicenter open-label sertraline study in adolescent outpatients with major depression.
TLDR
In open treatment of adolescent MDD with sertraline, significant improvement occurred early on and was maintained for 22 weeks, and Absolute response rates varied depending on the rating scales used, definition of response, and length of treatment.
[Psychotropic drug use in adolescence: why more girls? Study of a sample of 12-20-year-old students in Haute-Marne (France)].
TLDR
Female overuse was observed for different types of drugs (for distress/anxiety, sleep disturbance...) whether prescribed or not and increased with depressiveness, somatic complaints and medical care.
Off label and unlicensed drug use among French office based paediatricians.
TLDR
Off label prescriptions are widespread in office based paediatric practice, while unlicensed drug use is rare in this study.
Drug prescribing among Danish children: a population-based study
TLDR
There is the same skewness of drug consumption among Danish children as among Danish adults, but the types of medication differ; drug prescribing was considerable in all age groups.
French adolescent attitudes towards informal care for physical and emotional or relational problems
TLDR
The results showed that the most frequent self‐care activity for general health problems, in more than three‐quarters of them, was self‐medication; 14% of them resorted to minor home treatment such as taking care of wounds, bandaging or massages.
Adverse drug reactions and off-label drug use in paediatric outpatients.
TLDR
The data suggest an increasing risk of adverse drug reactions related to off-label drug use, which would be acceptable if further studies prove the potential benefit of such a drug use.
...
...